Death, Sudden, Cardiac

• 

  Subject Areas on Research

  • 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 
  • 2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 
  • 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • A common SCN5A polymorphism attenuates a severe cardiac phenotype caused by a nonsense SCN5A mutation in a Chinese family with an inherited cardiac conduction defect. 
  • A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients. 
  • A pilot study using an implantable device to characterize cardiac arrhythmias in hemodialysis patients: implications for future research. 
  • A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. 
  • ACSM-AMSSM Call to Action: Adapting Preparticipation Cardiovascular Screening to the COVID-19 Pandemic. 
  • Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure. 
  • Absence of bilateral vision loss from amiodarone: a randomized trial. 
  • Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. 
  • Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. 
  • Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. 
  • Aetiology and incidence of sudden cardiac arrest and death in young competitive athletes in the USA: a 4-year prospective study. 
  • Aldosterone, ion channels, and sudden death: another piece of the circle? 
  • Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. 
  • Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 
  • An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure Trial. 
  • An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. 
  • Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis. 
  • Anesthetic Implications in Alternating Hemiplegia of Childhood: A Case Report. 
  • Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. 
  • Antipsychotic medications and sudden cardiac death. 
  • Antipsychotics and sudden death: is thioridazine the only bad actor? 
  • Antipsychotics and the risk of sudden cardiac death. 
  • Anxiety and vagal control of heart rate. 
  • Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? 
  • Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. 
  • Arrhythmogenic Right Ventricular Cardiomyopathy: Overview and Case Study. 
  • Arrhythmogenic right ventricular dysplasia: a United States experience. 
  • Assessing the appropriateness of ICD use "appropriately". 
  • Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. 
  • Assessment of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis. 
  • Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. 
  • Association between bilirubin and mode of death in severe systolic heart failure. 
  • Association of prolonged QRS duration with death in a clinical trial of pacemaker therapy for sinus node dysfunction. 
  • Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). 
  • Asthma-related sudden death in athletes: a retrospective analysis of the US NCCSIR database (1982-2018). 
  • Asymptomatic Severe Aortic Valve Stenosis-When to Intervene: a Review of the Literature, Current Trials, and Guidelines. 
  • Atrial fibrillation and sudden cardiac death: is heart failure the middleman? 
  • Attitudes of the American public toward organ donation after uncontrolled (sudden) cardiac death. 
  • Audible implantable cardioverter defibrillator alarms detect intermittent conductor discontinuity. 
  • Availability of Automated External Defibrillators in Public High Schools. 
  • Azithromycin use increases the risk of sudden cardiac death in patients with hemodialysis-dependent kidney failure. 
  • Be-All End-All Real-World Evidence on the Subcutaneous ICD. 
  • Better survival for victims of cardiac arrest occurring in sports facilities: From speculations to facts. 
  • Beware of life-threatening activation of air bubble detector during contrast echocardiography in patients on venoarterial extracorporeal membrane oxygenator support. 
  • Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. 
  • Cardiac Magnetic Resonance Scar Imaging for Sudden Cardiac Death Risk Stratification in Patients with Non-Ischemic Cardiomyopathy. 
  • Cardiac causes of sudden death: virtual panel discussion of posed questions. 
  • Cardiac hypertrophy and sudden death in mice with a genetically clamped renin transgene. 
  • Cardiac sarcoidosis: two cases with autopsy findings. 
  • Cardioplegia and ventricular late potentials in cardiac surgical patients. 
  • Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT. 
  • Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). 
  • Cardiovascular preparticipation screening of competitive athletes. American Heart Association. 
  • Centers for Medicare and Medicaid Services' Decision to Reconsider Coverage Indications for ICDs: Where to Now? 
  • Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. 
  • Channeling a new focus for heart failure: insights into ion channels. 
  • Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. 
  • Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial. 
  • Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. 
  • Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. 
  • Collaborative care for the wearable cardioverter defibrillator patient: Getting the patient and medical team "vested and active". 
  • Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. 
  • Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. 
  • Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging. 
  • Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes. 
  • Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE. 
  • Coronary Artery Anomalies: When You Need to Worry. 
  • Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. 
  • Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. 
  • Cost-effectiveness of implantable cardioverter-defibrillators. 
  • Cost-effectiveness of the implantable cardioverter defibrillator. 
  • Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. 
  • Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults. 
  • Design of a modular, extensible decision support system for arrhythmia therapy. 
  • Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. 
  • Device therapy in heart failure patients with chronic kidney disease. 
  • Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. 
  • Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients. 
  • Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. 
  • Distributed decision support using a web-based interface: prevention of sudden cardiac death. 
  • Diuretics and sudden cardiac death. 
  • Do ICD lead recalls affect physician--or patient--behavior? If not, why not? 
  • Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator? 
  • Does myocardial perfusion imaging provide incremental prognostic information to left ventricular ejection fraction? 
  • Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? 
  • Donation after cardiac death: the university of wisconsin experience with renal transplantation. 
  • ECG quantification of myocardial scar and risk stratification in MADIT-II. 
  • Early Increased Physical Activity, Cardiac Rehabilitation, and Survival After Implantable Cardioverter-Defibrillator Implantation. 
  • Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction. 
  • Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon Pump. 
  • Educational videos to reduce racial disparities in ICD therapy via innovative designs (VIVID): a randomized clinical trial. 
  • Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. 
  • Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. 
  • Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. 
  • Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. 
  • Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. 
  • Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. 
  • Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Electrocardiographic Early Repolarization: A Scientific Statement From the American Heart Association. 
  • Electrocardiographic J Wave and Cardiovascular Outcomes in the General Population (from the Atherosclerosis Risk In Communities Study). 
  • Electrocardiographic findings in young competitive athletes during acute SARS-CoV-2 infection. 
  • Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women. 
  • Electrophysiologic and clinical effects of angiotensin-converting enzyme inhibitors in patients with prior myocardial infarction, nonsustained ventricular tachycardia, and depressed left ventricular function. MUSTT Investigators. Multicenter UnSustained Tachycardia Trial. 
  • Electrophysiologic testing to identify patients at risk for sudden death. 
  • Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. 
  • Epidemiology of Sudden Death in Organized Youth Sports in the United States, 2007-2015. 
  • Etiology of Sudden Cardiac Arrest and Death in US Competitive Athletes: A 2-Year Prospective Surveillance Study. 
  • Evaluation of a Standardized Cardiac Athletic Screening for National Collegiate Athletic Association (NCAA) Athletes. 
  • Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. 
  • Facilitating Shared Decision Making Among Black Patients at Risk for Sudden Cardiac Arrest : A Randomized Clinical Trial. 
  • Factors and outcomes associated with improved left ventricular systolic function in patients with cardiomyopathy. 
  • From diagnostic testing to precision medicine: the evolving role of genomics in cardiac channelopathies and cardiomyopathies in children. 
  • From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. 
  • Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients. 
  • GWAS or Gee Whiz, PSAS or Pshaw: elucidating the biologic and clinical significance of genetic variation in cardiovascular disease. 
  • Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death? 
  • Genetic analyses of the electrocardiographic QT interval and its components identify additional loci and pathways. 
  • Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. 
  • Genetic testing: clinical and personal utility. 
  • High School Cardiac Emergency Response Plans and Sudden Cardiac Death in the Young. 
  • Home use of automated external defibrillators for sudden cardiac arrest. 
  • Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. 
  • Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. 
  • Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline. 
  • ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure. 
  • Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). 
  • Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. 
  • Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. 
  • Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. 
  • Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis. 
  • Implantable Defibrillators for Primary Prevention of Sudden Death in Patients on Dialysis. 
  • Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. 
  • Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. 
  • Implantable cardioverter defibrillators: risks accompany the life-saving benefits. 
  • Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions. 
  • Implantable cardioverter-defibrillator lead revision following left ventricular assist device implantation. 
  • Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. 
  • Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. 
  • Implantable cardioverter-defibrillators for primary prevention: how do the data pertain to the aged? 
  • Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. 
  • Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. 
  • Improving Youth Sports Safety: Implementing an Emergency Action Plan for Sudden Cardiac Arrest. 
  • Improving ascertainment of sudden cardiac death in patients with end stage renal disease. 
  • Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. 
  • In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). 
  • Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. 
  • Incidental findings on cardiac computed tomography in incident hemodialysis patients: the predictors of arrhythmic and cardiovascular events in end-stage renal disease (PACE) study. 
  • Increasing the Availability of Automated External Defibrillators at Sporting Events: A Call to Action from the American College of Sports Medicine. 
  • Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. 
  • Is biology destiny or can we optimize care for all patients? 
  • Isolated Noncompaction of the Left Ventricle in Adults. 
  • Knowledge Gaps in Cardiovascular Care of the Older Adult Population: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Geriatrics Society. 
  • Knowledge and Insights Vested in Us by the VEST. 
  • Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. 
  • Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. 
  • Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. 
  • Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. 
  • Long-term prognosis associated with J-point elevation in a large middle-aged biracial cohort: the ARIC study. 
  • Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients. 
  • MADIT-II: clinical implications. 
  • MY APPROACH to the risk stratification of patients for sudden cardiac death. 
  • Management of Ventricular Arrhythmias and Sudden Cardiac Death Risk Associated With Cardiac Channelopathies. 
  • Management of Ventricular Arrhythmias and Sudden Cardiac Death Risk Related to Ischemic and Nonischemic Cardiomyopathy. 
  • Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. 
  • Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. 
  • Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. 
  • Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator. 
  • Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. 
  • Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. 
  • Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. 
  • Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. 
  • Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. 
  • Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. 
  • Multicenter automatic defibrillator implantation trial: reduce inappropriate therapy (MADIT-RIT): background, rationale, and clinical protocol. 
  • My child needs or has an implantable cardioverter-defibrillator: what should I do? 
  • Myocarditis in Whipple's disease: an unsuspected cause of symptoms and sudden death. 
  • Near-term prediction of sudden cardiac death in older hemodialysis patients using electronic health records. 
  • New Concepts in Sudden Cardiac Arrest to Address an Intractable Epidemic: JACC State-of-the-Art Review. 
  • New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. 
  • No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • No benefit of a dual coil over a single coil ICD lead: evidence from the Sudden Cardiac Death in Heart Failure Trial. 
  • Non-evidence-based ICD implantations in the United States. 
  • Nonsustained ventricular tachycardia in coronary artery disease: relation to inducible sustained ventricular tachycardia. MUSTT Investigators. 
  • One gene, two modes of inheritance, four diseases: A systematic review of the cardiac manifestation of pathogenic variants in JPH2-encoded junctophilin-2. 
  • One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System. 
  • Optimal management of Riata leads with no known electrical abnormalities or externalization: a decision analysis. 
  • Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis. 
  • Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention: From the NCDR ICD Registry. 
  • Outcomes Associated With Subcutaneous Implantable Cardioverter Defibrillators-Reply. 
  • Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. 
  • Outcomes for patients with anterior myocardial infarction and prior cardiac arrest in the home automated external defibrillator trial (HAT). 
  • Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. 
  • Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment. 
  • Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. 
  • Personalizing Risk Assessment for Sudden Cardiac Death in Heart Failure: A Dream or a Reality? 
  • Phobic anxiety and increased risk of mortality in coronary heart disease. 
  • Phobic anxiety, depression, and risk of ventricular arrhythmias in patients with coronary heart disease. 
  • Potassium channel blockade amplifies cardiac instability numerical studies of torsades de pointes. 
  • Potential applications of pharmacogenomics to heart failure therapies. 
  • Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. 
  • Pre-participation physical evaluations for athletes. 
  • Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy. 
  • Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. 
  • Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein grafts. 
  • Presentation and explanation of medical decision models using the World Wide Web. 
  • Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death prevention. 
  • Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death. 
  • Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. 
  • Prevention of sudden cardiac death in the young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium. 
  • Prevention of sudden cardiac death: a probabilistic model for decision support. 
  • Prevention of sudden death in patients with coronary artery disease. 
  • Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). 
  • Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis. 
  • Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. 
  • Primary prevention implantable cardioverter defibrillators are effective in preventing overall mortality in older patients. 
  • Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. 
  • Primary prevention implantable cardioverter defibrillators in women: More questions than answers. 
  • Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients. 
  • Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. 
  • Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. 
  • Prognostic usefulness of left ventricular thrombus by echocardiography in dilated cardiomyopathy in predicting stroke, transient ischemic attack, and death. 
  • Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. 
  • Prognostication for Sudden Cardiac Arrest Patients Achieving ROSC. 
  • Prolongation of QTc intervals and risk of death among patients with sickle cell disease. 
  • Promoting an Emergency Action Plan for Sudden Cardiac Arrest in Youth Sports During a Pandemic. 
  • Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. 
  • Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. 
  • Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis. 
  • Publishing web-based guidelines using interactive decision models. 
  • Quality of care for sudden cardiac arrest: Proposed steps to improve the translation of evidence into practice. 
  • Quality of life after videoscopic left cardiac sympathetic denervation in patients with potentially life-threatening cardiac channelopathies/cardiomyopathies. 
  • Quality of life effects of automatic external defibrillators in the home: results from the Home Automatic External Defibrillator Trial (HAT). 
  • Quality of life in patients with implantable cardioverter-defibrillator: systematic review of randomized controlled trials. 
  • RR-interval irregularity precedes ventricular fibrillation in ST elevation acute myocardial infarction. 
  • Racial differences in outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT): a comparison of whites versus blacks. 
  • Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of  
  • Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). 
  • Rationale and design of the Home Automatic External Defibrillator Trial (HAT). 
  • Recent advances in the treatment of arrhythmias. 
  • Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. 
  • Reduced ejection fraction, sudden cardiac death, and heart failure death in the mode selection trial (MOST): implications for device selection in elderly patients with sinus node disease. 
  • Reduction in Inappropriate ICD Therapy in MADIT-RIT Patients Without History of Atrial Tachyarrhythmia. 
  • Regional Systems of Care Demonstration Project: American Heart Association Mission: Lifeline STEMI Systems Accelerator. 
  • Relation between time from myocardial infarction to enrolment and patient outcomes in the Multicenter UnSustained Tachycardia Trial. 
  • Relation of 12-lead electrocardiogram patterns to implanted defibrillator-terminated ventricular tachyarrhythmias in hypertrophic cardiomyopathy. 
  • Relation of Early Repolarization (J Point Elevation) to Mortality in Blacks (from the Jackson Heart Study). 
  • Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. 
  • Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). 
  • Reply: Mode of Death Prevention by Serelaxin. 
  • Reply: circadian variations of ventricular arrhythmias and sleep-disordered breathing in HF patients. 
  • Reply: considerations for drug development for heart failure. 
  • Reply: rapid rate nonsustained ventricular tachycardia found on ICD interrogation: relationship of RR-NSVT to outcomes in the SCD-HeFT trial. 
  • Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program". 
  • Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women". 
  • Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis. 
  • Right ventricular dysfunction and the incidence of implantable cardioverter-defibrillator therapies. 
  • Risk assessment of patients having congenital heart disease using electrophysiologic testing: finally, opening the right door...or, an impossible chore? 
  • Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis. 
  • Risks and challenges of implantable cardioverter-defibrillators in young adults. 
  • Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. 
  • SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. 
  • Saving athletes' lives a reason to find common ground? 
  • Seizures, syncope, or breath-holding presenting to the pediatric neurologist--when is the etiology a life-threatening arrhythmia? 
  • Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT. 
  • Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. 
  • Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. 
  • Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). 
  • Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. 
  • Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis. 
  • Single-photon emission computed tomography myocardial perfusion defects are associated with an increased risk of all-cause death, cardiovascular death, and sudden cardiac death. 
  • Single-photon emission computed tomography myocardial perfusion imaging and the risk of sudden cardiac death in patients with coronary disease and left ventricular ejection fraction>35%. 
  • Single-photon emission computed tomography myocardial perfusion imaging-assessed stress perfusion defect severity is associated with mortality independent of ethnicity in an Asian population. 
  • Smarter deployment of implantable cardioverter-defibrillators in nonischemic cardiomyopathy: feasible or mythical? 
  • Socioeconomic factors and outcomes from exercise-related sudden cardiac arrest in high school student-athletes in the USA. 
  • Soluble P-selectin levels are associated with cardiovascular mortality and sudden cardiac death in male dialysis patients. 
  • Spousal depression, anxiety, and suicide after myocardial infarction. 
  • Stress cardiac magnetic resonance imaging provides effective cardiac risk reclassification in patients with known or suspected stable coronary artery disease. 
  • Subcutaneous and Transvenous ICDs: an Update on Contemporary Questions and Controversies. 
  • Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. 
  • Sudden Cardiac Death Among Hemodialysis Patients. 
  • Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). 
  • Sudden cardiac arrest in ESRD patients. 
  • Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. 
  • Sudden cardiac death after heart transplantation: can ICD prevent SCD? 
  • Sudden cardiac death due to large coronary aneurysm successfully treated with a covered stent and ChromaFlo guidance. 
  • Sudden cardiac death following admission for acute heart failure: adding insult to injury. 
  • Sudden cardiac death in hemodialysis patients: a comprehensive care approach to reduce risk. 
  • Sudden cardiac death in patients with myocarditis: Evaluation, risk stratification, and management. 
  • Sudden cardiac death in young children with neurofibromatosis type 1. 
  • Sudden death and resisted mechanical restraint: a case report. 
  • Survival After Exercise-Related Sudden Cardiac Arrest in Young Athletes: Can We Do Better? 
  • Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement: An Analysis From the NCDR ICD Registry. 
  • Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. 
  • Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. 
  • Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. 
  • Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. 
  • Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. 
  • Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • Systematic review of the incidence of sudden cardiac death in the United States. 
  • T wave alternans: a marker of myocardial instability. 
  • TBX5-encoded T-box transcription factor 5 variant T223M is associated with long QT syndrome and pediatric sudden cardiac death. 
  • Temporal Trends and Outcomes of Implantable Cardioverter Defibrillators in Heart Failure and Chronic Kidney Disease in the United States. 
  • The J wave patterns and risk of sudden cardiac death in patients with coronary artery disease. 
  • The Metabolic Syndrome and Risk of Sudden Cardiac Death: The Atherosclerosis Risk in Communities Study. 
  • The Risk of Sudden Cardiac Death in Mitral Valve Prolapse: Are All Patients Created Equal? 
  • The S1103Y cardiac sodium channel variant is associated with implantable cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction. 
  • The Second Annual Think Tank on Prevention of Sudden Cardiac Death in the Young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium. 
  • The changing epidemiology of ventricular arrhythmias and sudden cardiac death: Is it a reality? 
  • The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. 
  • The high cost of implantable defibrillators. 
  • The interplay between CKD, sudden cardiac death, and ventricular arrhythmias. 
  • The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study. 
  • The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. 
  • The subcutaneous implantable cardioverter-defibrillator in review. 
  • The use of implantable cardioverter defibrillators for the prevention of sudden cardiac death: a review of the evidence and implications. 
  • Toward more optimal use of primary prevention implantable cardioverter-defibrillators: how do we get there? 
  • Trends from 1987 to 2004 in sudden death due to coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. 
  • Unexpected deviation in circadian variation of ventricular arrhythmias: the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. 
  • Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. 
  • Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End-Stage Kidney Disease. 
  • Use of beta-blockers in patients with an implantable cardioverter defibrillator. 
  • Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis. 
  • Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Usefulness of the Duke Sudden Cardiac Death risk score for predicting sudden cardiac death in patients with angiographic (>75% narrowing) coronary artery disease. 
  • Utility of implantable cardioverter defibrillators in chronic kidney disease. 
  • Variant R94C in TNNT2-Encoded Troponin T Predisposes to Pediatric Restrictive Cardiomyopathy and Sudden Death Through Impaired Thin Filament Relaxation Resulting in Myocardial Diastolic Dysfunction. 
  • Video-Only Cardiopulmonary Resuscitation Education for High-Risk Families Before Hospital Discharge: A Multicenter Pragmatic Trial. 
  • Videos to reduce racial disparities in ICD therapy Via Innovative Designs (VIVID) trial: Rational, design and methodology. 
  • Wearable Cardioverter Defibrillator "The Lifevest": Device Design, Limitations, and Areas of Improvement. 
  • Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Science Advisory From the American Heart Association. 
  • What happens when cardiac Na channels lose their function? 1--numerical studies of the vulnerable period in tissue expressing mutant channels. 
  • When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion? 
  • When to implant an ICD following a myocardial infarction? 
  • Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. 
  • Worried to death? 
• 

  Keywords of People

  • Bennett, Vann, George Barth Geller Distinguished Professor of Molecular Biology, Duke Cancer Institute
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Middleton, John Paul, Professor of Medicine, Medicine, Nephrology
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Starmer, Charles Franklin, Professor Emeritus of Computer Science, Computer Science